Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
1. CGTX closed a direct offering of 14.7 million shares at $2.05 each. 2. Gross proceeds from the offering were approximately $30 million. 3. CEO mentions strong institutional support for their neurodegenerative disorder treatments. 4. Zervimesine is aimed at treating Alzheimer’s and DLB, with positive clinical results. 5. Phase 2 studies for zervimesine are ongoing with substantial grant support.